Navigation Links
New tumor markers determine therapy intensity
Date:3/17/2009

Characteristic changes in the DNA of medulloblastoma, the most frequent malignant brain tumor in childhood, indicate precisely how aggressively the tumor will continue to spread and what the chances of disease relapse are. Researchers at the Center for Pediatric and Adolescent Medicine at the Heidelberg University Hospital and the German Cancer Research Center have discovered this correlation. With this new set of tumor markers, the intensity of treatment can be adjusted individually and the potentially damaging effects reduced. The results have now been published online in the prestigious Journal of Clinical Oncology.

Medulloblastoma is the most frequent childhood brain tumor

The most common malignant brain tumor in childhood is the medulloblastoma every year, more than 100 children in Germany develop this tumor of the cerebellum and some 30-40 children die from it. The first symptoms generally appear at primary school age, but the tumor, which can already arise during embryonal development, can also occur in babies and toddlers. Aggressive radiation and chemotherapy regimens after surgery can permanently damage the brain of the growing child, for example, leading to coordination disorders and limited growth.

"Using the characteristic changes in the genetic makeup of medulloblastoma, we can predict more accurately than with conventional methods how a patient will respond to therapy and how great the risk is that the tumor will return after surgery and subsequent radiation and chemotherapy," explained Dr. Stefan Pfister, who works with his team in the department of pediatric oncology at the Center for Pediatric and Adolescent Medicine (Medical Director: Professor Dr. Dr. Andreas Kulozik) and in the department of molecular genetics at the German Cancer Research Center (Director: Professor Dr. Peter Lichter). Thus far, oncologists could estimate this risk only on the basis of histology findings, age at diagnosis, residual
'/>"/>

Contact: Dr. Stefan Pfister
s.pfister@dkfz.de
062-215-64555
University Hospital Heidelberg
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
2. Tiny tool to control growing blood vessels opens new potential in tumor research
3. Researchers isolate protein domain linked to tumor progression
4. Singapore research organisations team up to advance drug discovery using brain tumor stem cells
5. Scattered light rapidly detects tumor response to chemotherapy
6. New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome
7. Stress may hasten the growth of melanoma tumors
8. Implants mimic infection to rally immune system against tumors
9. UC Davis researchers find molecule that targets brain tumors
10. Researchers identify new anti-tumor gene
11. Novel technique for fluorescence tomography of tumors in living animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... the brain plays a key role in glucose regulation and the ... issue of the journal Nature . If the hypothesis is ... prevent and treat this disease, which is projected to affect one ... the paper, lead author Dr. Michael W. Schwartz, director of the ...
... Reusing the major greenhouse gas carbon dioxide (CO2) from industrial ... environment is on the verge of becoming a commercial ... in the U.S. are leading the way, according to an ... newsmagazine of the American Chemical Society. Alex Scott, C&EN,s ...
... be a key to early identification of autism, according to ... (NIMH), part of the National Institutes of Health. Published this ... the earliest sign of developing autism ever observeda steady decline ... six months of life. "Autism isn,t usually diagnosed ...
Cached Biology News:Brain may play key role in blood sugar metabolism and development of diabetes 2Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Sept. 12 Prolog Ventures, a venture capital,firm ... Dan,Broderick has joined the firm as its fourth ... in early-stage investing, venture fund,management, and technology commercialization. ... managing director at Mason,Wells in Milwaukee, WI, where ...
... Scheduled for London, Paris, Munich, San ... Francisco, CA ... Scientific,part of The Thomson Corporation (NYSE: TOC ; ... worldwide research and business,communities, announced today that it will ...
... ... Artery Bypass Surgery, REDWOOD CITY, Calif., Sept. 12 ... received European CE Mark,(Conformite Europeenne) approval for the C-Port(R) Flex A ... C-Port(R) xA,Distal Anastomosis System product line and further facilitates the,automated anastomosis, ...
Cached Biology Technology:Dan Broderick Joins Prolog Ventures as Partner 2Dan Broderick Joins Prolog Ventures as Partner 3Thomson Scientific to Host Pharmaceutical Vision - A User's Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 3
...
... PS10 ProteinChip Arrays are preactivated with ... free primary amine groups. The PS10 array ... former PS1 array, but with an updated ... spot chips with 2 mm diameter spots ...
...
... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
Biology Products: